NL-OMON44574
Recruiting
Phase 4
Therapeutic drug monitoring in tocilizumab-treated rheumatoid arthritis patients: Pilot study of a double-blind randomised controlled trial - TDM tocilizumab
Amsterdam Rheumatology and immunology Center | Reade0 sites30 target enrollmentTBD
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- rheuma
- Sponsor
- Amsterdam Rheumatology and immunology Center | Reade
- Enrollment
- 30
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •RA according to the ACR 1987 or 2010 criteria;
- •Current use of tocilizumab iv, with a consistent interval of 4 weeks for at least 24 weeks.
Exclusion Criteria
- •Scheduled surgery in the next 20 weeks or other preplanned reasons for treatment discontinuation.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 4
Determination of tocilizumab trough levels during dose tapering in patients with rheumatoid arthritis (OPTIRA study)NL-OMON53280Franciscus Gasthuis & Vlietland46
Completed
Not Applicable
The effect of monitoring of tobramycin levels in blood in patients with cystic fibrosis.NL-OMON20263AMC35
Recruiting
Phase 2
Evaluation of the Effects of Tocilizumab Administration in Hospitalized COVID-19 PatientsIRCT20151227025726N29Iran University of Medical Sciences50
Completed
Not Applicable
Clinical trial of efficacy for tocilizumab in systemic sclerosis and sclerodermatous chronic GVHDThe patients with systemic sclerosis or sclerodermatous chronic GVHD.JPRN-UMIN000020389Kanazawa University Hospital, Department of dermatology5
Recruiting
Not Applicable
Therapeutic Drug Monitoring in tuberculosis patients. Setup and optimisation of therapeutic drug monitoring at the Research Center BorstelA15.9Respiratory tuberculosis unspecified, confirmed bacteriologically and histologicallyDRKS00009869Medizinische Klinik des Foschungszentrums Borstel20